You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Shingrix Logo

Product menu

doctor explaining to patient over digital tablet at hospital
Irish shingles vaccination recommendations for adults ≥ 50 years of age and those aged 18+ at increased risk of herpes zoster.

National Immunisation Advisory Committee (NIAC) Guidelines

When consulting with patients ≥50 years old, consider the NIAC recommendation for shingles vaccination.1 The NIAC Guidelines state that:1,2

  • Shingrix may be considered in those aged 50 years and older, due to the greater burden and severity of disease and PHN in this age group and in those aged 18 years and older at increased risk of herpes zoster.2
  • The vaccine may be given to those who have had zoster. It is prudent to defer vaccination for 12 months after the zoster has resolved so that the vaccine can produce a more effective immune response.2
  • As the vaccine is not part of the national immunisation programme, individuals aged ≥50 years wishing to receive it should consult with their GP or pharmacist.1,2
  • Shingrix is recommended for patients 50 years and older with haematologic malignancies and solid tumours, as they are at increased risk of developing herpes zoster (shingles). Patients with Hodgkin’s disease are at particularly high risk, with rates approaching 30% during illness or its treatment. Shingrix should also be given to those aged ≥50 years who are solid organ transplant candidates and recipients.1
<b>>90% Efficacy against Herpes Zoster icon</b>

How efficacious is SHINGRIX?

SHINGRIX demonstrated >90 % efficacy against shingles in adults 50 years of age and older based on pooled data from two large, phase 3 randomised controlled trials.4,5,6

VIEW EFFICACY DATA

patient icon

Who can benefit from SHINGRIX?

There is a 1 in 3 lifetime risk of developing shingles.7,8 Age-related decline in immunity puts patients 50 years of age and older at an increased risk of developing shingles.9,10

VIEW PATIENT PROFILES

two syringes showing a two dose schedule

Ready to vaccinate with SHINGRIX?

Familiarise yourself with the dosing and administration of SHINGRIX.4

DOSING AND ADMINISTRATION INFO

References

  1. NIAC. Chapter 3 Immunisation of Immunocompromised Persons. 2022 March. Available on: https://rcpi.access.preservica.com/uncategorized/IO_0ff0fd53-1618-456b-a8b3-52c2bc09e7fd/ Last Accessed: January 2023
  2. NIAC. Chapter 23 Varicella-Zoster. 2022 October. Available on https://rcpi.access.preservica.com/uncategorized/IO_e74b6219-7108-4d6f-b099-0db8ef746acf/ Last Accessed: January 2023
  3. National Immunisation guidelines for Ireland, available on https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/immunisationguidelines.html Last Accessed: June 2022
  4. Shingrix, Summary of Product Characteristics (SPC), available on https://www.medicines.ie/medicines/shingrix-powder-and-suspension-for-suspension-for-injection-herpes-zoster-vaccine-recombinant-adjuvanted--35192/spc. Last Accessed: June 2022
  5. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372 (22):2087-96.
  6. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375 (11):1019-32.
  7. Harpaz R, et al. MMWR Recomm Rep. 2008 June;57(RR-5):1-30. 2. Zerboni L, et al. Nat Rev Microbiol. 2014 Mar;12 (3):197-210.
  8. Bollaerts K et al. A systematic review of varicella seroprevaience in European countries before universal childhood immunization: deriving incidence from seroprevaience data. Epidemiol. Infect. (2017), 145, 2666-2677
  9. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar;356 (13):1338-43.
  10. Crooke, S.N., et al. Immun Ageing. 2019 Sep 13; 16:25.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

SHINGRIX is owned by or licensed to the GSK group of companies.
© 2022 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

PM-IE-SGX-WCNT-220006
Date of Preparation: February 2023